![A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study - ScienceDirect A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825817301610-gr1.jpg)
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study - ScienceDirect
![Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library](https://faseb.onlinelibrary.wiley.com/cms/asset/d99ca0ed-fe46-42b8-be0c-cdbf63ce84f0/fsb2fj000716fje-fig-0003-m.jpg)
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library
![Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo - ScienceDirect Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0014299920304313-fx1.jpg)
Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo - ScienceDirect
![Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick](https://www.biocrick.com/media/images/struct3D/BCC1099.png)
Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick
![Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2005/nejm_2005.352.issue-11/nejmoa050405/production/images/img_medium/nejmoa050405_f1.jpeg)
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM
![Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library](https://faseb.onlinelibrary.wiley.com/cms/asset/3b787d22-d470-4a61-bb4d-e472eac9a671/fsb2fj000716fje-fig-0004-m.jpg)